News

US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...
Long-acting HIV prevention drug from Gilead wins FDA approval. Will it get to the people who need it?
The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
FDA approves first twice-yearly injection that prevents HIV infection
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…
Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...
BioSpace14h
Gilead Wins Historic Approval for Twice-Yearly HIV Drug
“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
PharmExec10h
FDA Approves Gilead’s Yeztugo as First Twice-Yearly Injection for HIV Pre-Exposure Prophylaxis
Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...
Stocktwits on MSN3h
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
Pharmabiz19m
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...